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RESUMO – O sarcoma de Kaposi é um tumor vascular de baixo grau, associado à infeção pelo herpesvírus humano 8. Os doentes 
com transplante de órgão sólido têm um elevado risco desta neoplasia, com taxas de incidência estimadas 84 a 500 vezes superio-
res às da população geral. O risco é ainda maior em grupos étnicos com incidências intrinsecamente mais elevadas. Apresentamos 
o caso de um doente de 37 anos, natural de um país africano, transplantado renal, com sarcoma de Kaposi refratário a diferentes 
opções terapêuticas. O caso coloca em evidência os desafios associados ao tratamento desta neoplasia em populações de alto 
risco e enfatiza a importância da abordagem multidisciplinar para o sucesso terapêutico, particularmente em formas avançadas 
e refratárias de doença. 
PALAVRAS-CHAVE – Hospedeiro Imunocomprometido; Sarcoma de Kaposi/etiologia; Transplantados; Transplante de Ór-
gãos/efeitos adversos.
Kaposi Sarcoma in Solid Organ Transplant 
Recipients: A challenging Case  
ABSTRACT – Kaposi sarcoma is a low-grade vascular tumor, associated with human herpesvirus-8 infection. Solid organ transplant 
recipients have a much higher risk of this malignancy, with estimated incidence rates increased 84 to 500 times. The risk is even 
higher in some ethnic groups, already with a higher incidence of this disease.
We report a case of a 37-year-old African male, a kidney transplant recipient, with a Kaposi sarcoma refractory to different treat-
ment options. The present case puts in evidence the challenges associated with the management of this disease in this high-risk 
population and highlights the role of a multidisciplinary approach to achieve effective treatment, particularly in advanced and re-
fractory forms. 
KEYWORDS – Immunocompromised Host; Organ Transplantation/adverse effects; Sarcoma, Kaposi/etiology; Transplant Recipients.
INTRODUCTION
Kaposi sarcoma (KS) is a low-grade vascular tumor, with 
a complex pathogenesis, involving human herpes virus 8 
(HHV-8) infection, cytokines and host-immune suppression.1 
HHV-8 has oncogenic capacity, which mimics oncogenes 
that promote cell division, inhibit apoptosis, modulate in-
flammation and induce angiogenesis.1-3
KS affects primarily the skin and mucous membranes, 
but lymph nodes and visceral organs can also be involved, 
particularly in advanced forms.4,5
Solid organ transplant recipients have a much higher 
risk of this malignancy due to long-term use of immunosu-
ppressive agents for preventing allograft rejection. In this 
population its estimated incidence rates are increased 84 
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to 500 times.4,6 The risk is even further increased in ethnic 
groups that already have a higher incidence of this disease.4
The first line treatment of KS in solid organ transplant 
recipients usually consists of halving immunosuppression, 
which is associated with good responses, sometimes even 
complete remission.7,8 However, resistant and advanced 
cases are challenging and require other type of therapies.7,8 
CASE REPORT
A 37-year-old black male, born in a West African country, 
presented to our Dermatology Clinic with a six-month history 
of brown and violaceous nodules in his right leg. He had been 
submitted to kidney transplant two years before and his im-
munosuppressive therapy was mycophenolate mofetil 500 mg 
twice daily, rapamycin 3 mg once daily and prednisolone 5 
mg once day. The histopathologic examination of a skin biop-
sy was compatible with KS with positive immunohistochemical 
staining for HHV-8.
After the diagnosis, immunosuppressive therapy was re-
duced, stopping mycophenolate mofetil. The patient had a 
transient improvement, but after 18 months he developed 
exudative skin lesions in his lower limbs and abdomen (Fig.s 
1 and 2) and there was evidence of visceral disease, with 
gastric involvement confirmed by endoscopy and biopsy.
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Figure 1 - Lower limb involvement with exsudative lesions on the feet.
Figure 2 - Multiple brown and violaceous nodules on the lower limb.
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The patient was then evaluated by the specialty of Me-
dical Oncology and began first line chemotherapy with pe-
gylated liposomal doxorubicin. After a total 34 cycles, there 
was a good clinical response, with symptomatic improve-
ment and partial regression of skin lesions.
However, three months after finishing first line chemo-
therapy, the patient presented asymmetrical edema of the 
right lower limb and venous Doppler revealed lymphade-
nopathy compressing the femoral vessels. Computed tomo-
graphy (CT) revealed lymph node and peritoneal disease 
progression (Fig.s 3 and 4). 
Chemotherapy was then changed to second-line pacli-
taxel, followed by radiotherapy on femoral ganglion chains. 
Although there was an initial apparent response, the disease 
remained in progression with worsening of skin lesions and 
progressive visceral involvement, with liver metastasis. 
After 8 cycles, the patient was admitted for sepsis with bila-
teral infected ulcerations in his lower limbs motivating aggres-
sive antibiotic treatment and suspension of chemotherapy (Fig. 
5). In a multidisciplinary assessment with the specialties of 
Dermatology, Nephrology and Medical Oncology it was deci-
ded to suspend immunosuppression and to start etoposide as 
a third line chemotherapy. Additionally, wound cleansing was 
performed with potassium permanganate alternated with ace-
tic acid. There was a significant improvement of all skin lesions. 
Figure 3 - Inguinal lymph node involvement on imaging tests (CT). 
Figure 4 - Peritoneal involvement on imaging tests (CT). 
Figure 5 - Infected ulcerations on his right feet (superinfection with Pseudomonas aeruginosa).
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However, six months later, the patient developed clinical 
signs of renal allograft rejection so that immunosuppressive 
therapy was resumed with prednisolone 20 mg once daily. 
He remained stable on etoposide and prednisolone with 
a sustained response for three years but died after sepsis 
following a lower respiratory infection.
DISCUSSION 
Kaposi sarcoma is a challenging disease in solid organ 
transplant recipients, especially in those from endemic areas.4,5 
Halving immunosuppression is the first-line treatment in immu-
nosuppressed patients, and in most cases total regression of KS 
lesions is observed, nevertheless, it is challenging to maintain 
the balance between risks and benefits both for the graft and 
KS.5,7,9 
Prognosis in patients with KS limited to the skin is favora-
ble, whereas visceral involvement is associated with high mor-
tality.10 Visceral disease is observed in up to 25% of kidney 
transplant recipients with KS.4 For these patients and those with 
extensive and progressive mucocutaneous disease like our pa-
tient, systemic chemotherapy is the therapy of election.5,7,8 An-
thracyclines and paclitaxel are the main drugs for the treatment 
of KS.5,7,8,11 Other drugs, such as vinblastine, bleomycin and 
etoposide are effective alternatives for refractory cases.7,8 
In this case we had a very aggressive and resistant disea-
se form, but etoposide showed good results. Also in this case, 
control of organ rejection was obtained with low dose of im-
munosuppressive therapy. 
CONCLUSION
Multidisciplinary approach is essential to ensure optimiza-
tion of treatment in high-risk individuals with Kaposi sarcoma, 
particularly solid organ transplant recipients with advanced 
and refractory forms of this disease.
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